Plasma pTau blood biomarker tests (especially pTau217) for human clinical assessment of Alzheimer’s disease:
Dr. Carr currently offers the Labcorp pTau217 / amyloid beta 42/40 ratio and related Alzheimer’s blood biomarker testing as part of a robust dementia assessment or provides connections for testing through Apollo Health.
The Labcorp testing can be scheduled at their Patient Service Centers and has a good faith estimate of $398.40 for cash paying patients. Insurance billing is possible if the patient meets current guidelines for testing.
Other Laboratories developing or with developed early diagnostic Alzheimer’s Disease Tests.
| Company | Price/Test or Panel |
|---|---|
| Apollo Health Nfl and GFAP | $799 |
| BetterBrain | $200 |
| Function Health | $499 |
| Neurogen Biomarking | $499 |
| True Health Labs | $229 |
| C2N | multiplex mass spec based assay – can differentiate isoforms. $1450 – Research Only |
| Alamar Biosciences CNS 130 protein panel – | Alamar Biosciences – NULISA CNS immunoassays for the Brain isoform of pTau217 $120 – Research Only |
| MesoScale Diagnostics – Electro chemiluminescent Assay | S-PLEX Assay Platform | Meso Scale Discovery can assay Brain isoform of pTau217 |
| Quanterra Simoa Fluorescent System Aptamer/Antibody based Protein Asays | Alzpath pTau 217 Antibody ( not C terminal Isoform 0R, 1R, 3R or 4R specific) |
| Neurocode | Alz-path pTau217 assay $339 |